Selection and Timing of Initial, Foundational Therapy for Gastrointestinal Neuroendocrine Tumors (NETs): Critical Issues for Treatment Initiation and Subsequent Management of the Complex Patient: What Does the Evidence Show? How Do the Evidence, Trials, Safety-Efficacy Profiles of SSAs and Cytotoxic Therapies and NCCN Guidelines Direct Us? When Do We Start a Therapy? When Do We Discontinue? Should Some Foundational Therapies Be Maintained Through the Natural History? How Should We Approach Anti-Proliferative vs. Cytotoxic Therapeutic Options?
Alexandria Phan, MD